UBS maintains Chewy stock rating on margin, subscriber concerns

Chewy reported Q2 adjusted EPS of $0.36, in line with consensus, on revenue of $3.33B versus $3.32B expected; adjusted EBITDA margin reached 6.8% and EBITDA of $227M was roughly 7%-8% above expectations. However, gross margin disappointed and organic growth slowed to 5.7%, with active customers reaching 21.7M and net additions slightly below expectations. UBS retained a Neutral rating and $24 target, while Evercore ISI downgraded Chewy to In Line, contributing to a 13.4% one-week stock decline and modest downward revisions to 2027 estimates.

Analysis

CHWY is entering a more difficult valuation regime: the market is unlikely to reward EBITDA-margin outperformance if it is financed by deferring customer acquisition, loyalty investment, or assortment expansion. The key variable is incremental contribution margin on new customers, not headline active-customer growth; weak additions alongside reinvestment implies FY27 EBITDA estimates could continue to drift lower even if revenue remains near consensus. At roughly $20, the near-term downside is likely limited by valuation support and a substantial recurring-revenue base, but a rerating requires evidence that growth can reaccelerate without a material step-down in margin.

Competitive pressure is asymmetric. AMZN can subsidize pet-category pricing and delivery economics through Prime, while WMT and TGT can leverage physical-store replenishment for low-margin consumables. CHWY's defensible pool is higher-touch pharmacy, veterinary, and Autoship categories; therefore, mix toward these services should matter more than broad marketing spend. If Chewy+ adoption merely shifts existing customers into lower realized shipping economics rather than increasing order frequency and retention, gross-margin pressure will become structural rather than transitional.

Over the next 1-3 months, analyst estimate cuts and management's next customer-growth datapoint are the principal catalysts; the initial post-results decline may have already priced in a modest reset. Over 6-18 months, upside depends on customer-cohort retention, Autoship penetration, and whether SG&A reinvestment creates measurable lifetime-value gains. The bearish thesis is falsified if organic growth returns above roughly 7-8% while adjusted EBITDA margin holds near 6.5%+; conversely, another quarter of sub-6% organic growth or gross margin below 29.5% would likely force a lower earnings multiple.

Key Decisions for Investors

• Maintain a neutral-to-underweight CHWY stance into the next operating update; avoid adding after the initial selloff unless management provides cohort-level evidence that Chewy+ and marketing are lifting retention or purchase frequency. A break below the recent post-earnings low without further estimate cuts would be a signal to reassess short exposure rather than chase downside.
• For a tactical bearish expression over 1-3 months, consider a defined-risk CHWY put spread targeting a further 10-15% decline, funded only if implied volatility normalizes after earnings. The trade requires confirmation of downward FY27 EBITDA revisions; absent revisions, the valuation cushion makes outright shorts unattractive.
• Pair long AMZN or WMT against short CHWY only if pet-category price competition or CHWY gross-margin deterioration persists into the next quarter. The pair isolates weakening online pet-retail unit economics, but close if CHWY restores 7-8% organic growth while preserving a 6.5%+ EBITDA margin.
• Set an earnings-monitoring alert for Autoship growth, net-add trends, gross margin, and marketing as a percentage of sales. A sequential recovery in net additions with stable gross margin would support a 6-18 month long thesis; margin expansion without customer growth should be treated as low-quality and not a buy signal.